News

Introducing “Bench to Bedside With SIDP,” a new column covering everything from antimicrobial stewardship and pharmacokinetics/pharmacodynamics to mentorship, preceptorship, and more.

The US and the world must appreciate the role of the pharmaceutical industry—the investigators, physicians and business leaders—who are rescuing the world from COVID-19. It’s the medical breakthrough of our lifetime.

While social determinants, stigma about the virus, and continuum of care issues remain challenges to many people with HIV, The IDSA is looking to address these issues with its new guidance.

In the first week of 2021, the US is currently leading all countries in total vaccine administrations, despite state-level distribution setbacks.

The findings have important implications for studies in other diseases such as Type 1 diabetes.

Early data reported a disproportionate impact of death rates and infection rates in Black, Native American, and Latinx communities.

Observing infections in non-human primates can help to expedite therapeutics and vaccines for COVID-19.

A discussion around the relatively shocking effect of the virus on infants, and what's needed in long-term assessment of the patient group.

From vaccine studies to reopening institutions, pooled testing may be a hugely beneficial tool.

A principal investigator studying dolutegravir/lamivudine discusses its efficacy and potential treatment benefits.

Information gained has potential to contribute to future treatments for COVID-19 and other diseases

The virus may have been cleared by the time of death or viral copy numbers were below the level of detection.

Investigative studies looking at underlying immune characteristics are needed to understand disease pathogenesis.

Investigators developed a hybrid protocol to search for potential drug candidates against the replication of SARS-CoV-2.

The global health agency provided current insights and advisories into 4 different variants observed during COVID-19 this year.

The newly published data show no patient given the two-dose mRNA vaccine has yet to report a case of severe COVID-19.

A research team recently presented their efforts to integrate machine learning to identify people at high-risk of acquiring HIV.

A new multicenter study confirms earlier findings that the panel performs well against the more time-intensive quantitative bacterial culture.

Though regulatory authorization has not been granted, the company intends to vaccinate up to 50 million people prior to the Lunar New Year.

The authorization recommends dosage intervals of between 4 and 12 weeks.

A new article shows that breastfeeding after receiving dolutegravir in late pregnancy contributed relatively little infant plasma exposure but additional prophylaxis was reported among some.

Nearly 20% of patients who survive hospitalization are readmitted within 60 days, researchers find.

The ADVANCE study results at 96 weeks distinguish between the long-term effects of 3 combination regimens for HIV in weight gain and bone density change.

A research team recently sought to address this knowledge gap by analyzing a sample of US patients with COVID-19 infections.

Trial to enroll up to 30000 volunteers across approximately 115 sites in the US and Mexico.

With the public beginning to get vaccinated, CDC published information for people in some medical categories and considerations on severe allergic reactions.

Between March 1 and July 31, there were 76088 deaths among Americans aged 25 to 44, amounting to 11899 (18.5%) more than expected during that timeframe, new research shows.